• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.

作者信息

Rejeski Kai, Burchert Andreas, Iacoboni Gloria, Sesques Pierre, Fransecky Lars, Bücklein Veit, Trenker Corinna, Hernani Rafael, Naumann Ralph, Schäfer Jonas, Blumenberg Viktoria, Schmidt Christian, Sohlbach Kristina, von Bergwelt-Baildon Michael, Bachy Emmanuel, Barba Pere, Subklewe Marion

机构信息

Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany.

Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.

出版信息

Blood Adv. 2022 Aug 23;6(16):4719-4725. doi: 10.1182/bloodadvances.2022007776.

DOI:10.1182/bloodadvances.2022007776
PMID:35793454
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9631678/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/9631678/4a9d62dded87/advancesADV2022007776f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/9631678/129bcf464318/advancesADV2022007776absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/9631678/4a9d62dded87/advancesADV2022007776f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/9631678/129bcf464318/advancesADV2022007776absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/9631678/4a9d62dded87/advancesADV2022007776f1.jpg

相似文献

1
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.干细胞增强疗法作为CD19嵌合抗原受体T细胞疗法后严重血液毒性挽救治疗的安全性和可行性。
Blood Adv. 2022 Aug 23;6(16):4719-4725. doi: 10.1182/bloodadvances.2022007776.
2
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.半相合CD19嵌合抗原受体T细胞与干细胞共同输注在难治性急性淋巴细胞白血病中实现了完全供者植入。
J Hematol Oncol. 2016 Nov 25;9(1):131. doi: 10.1186/s13045-016-0357-z.
3
Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.在成人急性淋巴细胞白血病患者接受基于抗体的免疫治疗后，用抗 CD19 嵌合抗原受体 T 细胞进行治疗。
Curr Res Transl Med. 2020 Jan;68(1):17-22. doi: 10.1016/j.retram.2019.12.001. Epub 2019 Dec 25.
4
Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report.CD19 靶向 CAR T 细胞治疗后骨髓衰竭导致严重光滑念珠菌全结肠炎和致命烟曲霉肺部感染 - 一例报告。
BMC Infect Dis. 2021 Jan 28;21(1):121. doi: 10.1186/s12879-020-05755-4.
5
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.B细胞非霍奇金淋巴瘤患者自体造血干细胞移植后中枢记忆来源的CD19嵌合抗原受体T细胞疗法的1期研究。
Blood. 2016 Jun 16;127(24):2980-90. doi: 10.1182/blood-2015-12-686725. Epub 2016 Apr 26.
6
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.异基因移植后复发的 B 细胞急性淋巴细胞白血病的 CD19 和 CD22 CAR-T 细胞治疗的联合应用。
Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29.
7
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.依鲁替尼可提高难治性非霍奇金淋巴瘤患者抗 CD19-CAR T 细胞疗法的疗效。
Cancer Sci. 2021 Jul;112(7):2642-2651. doi: 10.1111/cas.14915. Epub 2021 May 10.
8
Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.局部产生的 CD19 CAR T 细胞导致髓性和髓外复发急性淋巴细胞白血病的临床缓解。
Am J Hematol. 2018 Dec;93(12):1485-1492. doi: 10.1002/ajh.25274. Epub 2018 Sep 26.
9
Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.供体来源的靶向CD19的T细胞输注可诱导复发的B细胞急性淋巴细胞白血病患者达到微小残留病阴性缓解，这些患者在单倍体造血干细胞移植后对供体淋巴细胞输注无反应。
Br J Haematol. 2017 Nov;179(4):598-605. doi: 10.1111/bjh.14923. Epub 2017 Oct 26.
10
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.获得CD19阴性髓系表型可使MLL重排的B细胞急性淋巴细胞白血病从CD19嵌合抗原受体T细胞疗法中实现免疫逃逸。
Blood. 2016 May 19;127(20):2406-10. doi: 10.1182/blood-2015-08-665547. Epub 2016 Feb 23.

引用本文的文献

1
Noncanonical and mortality-defining toxicities of CAR T cell therapy.嵌合抗原受体T细胞疗法的非典型及决定死亡率的毒性作用
Nat Med. 2025 Jul 16. doi: 10.1038/s41591-025-03813-5.
2
CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges.老年复发/难治性大B细胞淋巴瘤患者的CAR-T细胞疗法：益处与挑战
J Immunother Cancer. 2025 Jun 5;13(6):e009793. doi: 10.1136/jitc-2024-009793.
3
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.多发性骨髓瘤中的T细胞重定向疗法：细胞因子释放综合征和免疫效应细胞相关神经毒性综合征之外的发病机制及毒性管理

本文引用的文献

1
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.嵌合抗原受体 T 细胞（CAR-T）治疗后复发/难治性大 B 细胞淋巴瘤（R/R LBCL）患者的 CAR-HEMATOTOX 风险可预测严重感染和疾病进展。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2021-004475.
2
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.德国 GLA/DRST 真实世界研究分析嵌合抗原受体 T 细胞疗法治疗大 B 细胞淋巴瘤的结果。
Blood. 2022 Jul 28;140(4):349-358. doi: 10.1182/blood.2021015209.
3
The bone marrow niche components are adversely affected in sepsis.
Cancers (Basel). 2025 Apr 30;17(9):1514. doi: 10.3390/cancers17091514.
4
Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy.接受BCMA嵌合抗原受体T细胞疗法的患者在自体干细胞强化治疗后发生侵袭性上皮内癌-高侵袭性亚型的致命复发。
Blood Adv. 2025 Aug 12;9(15):3832-3836. doi: 10.1182/bloodadvances.2025016346.
5
Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.免疫效应细胞相关的血液毒性：机制、临床表现及管理策略。
Haematologica. 2025 Jun 1;110(6):1254-1268. doi: 10.3324/haematol.2024.286027. Epub 2025 Feb 20.
6
Successful allogeneic CD34 hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).成功进行异基因CD34造血干细胞增强治疗，用于治疗B细胞急性淋巴细胞白血病患者接受CAR T细胞治疗后出现的长期血细胞减少症。西班牙造血移植与细胞治疗小组（GETH-TC）代表发言。
Bone Marrow Transplant. 2025 Feb;60(2):250-253. doi: 10.1038/s41409-024-02473-2. Epub 2024 Nov 17.
7
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies.嵌合抗原受体T细胞血液学毒性的新见解：表现、机制及有效管理策略
Exp Hematol Oncol. 2024 Nov 9;13(1):110. doi: 10.1186/s40164-024-00573-9.
8
Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.抗CD19嵌合抗原受体T细胞疗法治疗复发/难治性B细胞非霍奇金淋巴瘤后的晚期事件
Front Oncol. 2024 Jun 11;14:1404351. doi: 10.3389/fonc.2024.1404351. eCollection 2024.
9
Granulocyte Colony Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cells: An Alternative Cellular Source for Chimeric Antigen Receptor Therapy.粒细胞集落刺激因子动员外周血单个核细胞：嵌合抗原受体治疗的另一种细胞来源。
Int J Mol Sci. 2024 May 25;25(11):5769. doi: 10.3390/ijms25115769.
10
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations.嵌合抗原受体 T 细胞毒性：从床边到实验室，新型毒性如何为实验室研究提供信息。
Blood Adv. 2024 Aug 27;8(16):4348-4358. doi: 10.1182/bloodadvances.2024013044.
在脓毒症中，骨髓生态位成分受到不利影响。
Mol Biomed. 2020 Oct 20;1(1):10. doi: 10.1186/s43556-020-00010-3.
4
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.严重细胞因子释放综合征与 CD19 CAR T 细胞治疗后的血液学毒性有关。
Blood Adv. 2022 Apr 12;6(7):2055-2068. doi: 10.1182/bloodadvances.2020004142.
5
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.嵌合抗原受体 T 细胞相关血液学毒性：复发/难治性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞相关血液学毒性的模型。
Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543.
6
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.泽沃基奥仑赛注射液（KTE-X19）治疗复发或难治性成人 B 细胞急性淋巴细胞白血病：ZUMA-3 研究单臂、开放标签、多中心的 2 期结果。
Lancet. 2021 Aug 7;398(10299):491-502. doi: 10.1016/S0140-6736(21)01222-8. Epub 2021 Jun 4.
7
Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.异基因造血干细胞移植作为复发/难治性弥漫性大 B 细胞淋巴瘤的根治性选择：西班牙多中心 GETH/GELTAMO 研究。
Bone Marrow Transplant. 2021 Aug;56(8):1919-1928. doi: 10.1038/s41409-021-01264-3. Epub 2021 Mar 25.
8
Hematologic Rescue of CAR T-cell-mediated Prolonged Pancytopenia Using Autologous Peripheral Blood Hematopoietic Stem Cells in a Lymphoma Patient.淋巴瘤患者中使用自体外周血造血干细胞对CAR T细胞介导的长期全血细胞减少进行血液学挽救
Hemasphere. 2021 Feb 17;5(3):e545. doi: 10.1097/HS9.0000000000000545. eCollection 2021 Mar.
9
Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin's lymphoma patients.改良的柔红霉素方案预处理后自体造血干细胞移植治疗侵袭性 B 细胞非霍奇金淋巴瘤患者。
Sci Rep. 2021 Feb 19;11(1):4273. doi: 10.1038/s41598-021-81944-8.
10
Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report.CD19 靶向 CAR T 细胞治疗后骨髓衰竭导致严重光滑念珠菌全结肠炎和致命烟曲霉肺部感染 - 一例报告。
BMC Infect Dis. 2021 Jan 28;21(1):121. doi: 10.1186/s12879-020-05755-4.